Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential tremor following disappointing Phase 2 results. However, the company maintains several promising ...
Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...
Analysts project peak sales of $1.7 billion, although the path to reaching this figure may be gradual. Biogen's pipeline has faced setbacks, including the discontinuation of SAGE-324 for essential ...
In Wednesday’s 2024 full-year earnings, the Cambridge drugmaker gave more details on cuts to its early-stage pipeline. Biogen said it would discontinue further development of certain programs in ...
Biogen's pipeline has faced recent setbacks, including the discontinuation of SAGE-324 (BIIB124) for essential tremor following disappointing Phase 2 results. This adds to a series of recent ...
Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal Vandana Singh Tue, Feb 18, 2025, 1:32 PM 2 min read ...
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...
Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果